WHO approves Sinopharm vaccine for emergency use in all countries
Georgia started Sinopharm vaccination on May 4. Photo: CFP Agenda.ge, 8 May 2021 - 12:02, Tbilisi,Georgia
The World Health Organisation (WHO) has approved the Chinese Sinopharm vaccine for emergency use in all countries, giving the green light for this vaccine to be rolled out globally, including in Georgia.
WHO today listed the Sinopharm #COVID19 vaccine for emergency use in all countries, a prerequisite for a potential #COVAX roll-out. Interim policy recommendations were also issued for the vaccine usage.
The Sinopharm is an inactivated vaccine called SARS-CoV-2 Vaccine (Vero Cell), produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG).
OMS aprueba uso de vacuna china contra Covid-19 | Noticias telesurtv.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from telesurtv.net Daily Mail and Mail on Sunday newspapers.
WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations
Format
Sinopharm-developed vaccine could help boost supply to underserved countries Geneva 7 May, 2021 WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG). The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk, said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.
China s Sinopharm vaccine has been approved for emergency use by the World Health Organisation.
It recommended the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks.
The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products, a subsidiary of China National Biotec Group. This afternoon, WHO gave emergency use listing to Sinopharm Beijing s Covid-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality, the UN health agency s director general Tedros Adhanom Ghebreyesus told a news conference.
“This expands the list of vaccines that Covax can buy and gives countries confidence to expedite their own regulatory approval and to import and administer a vaccine.”
May 07, 2021
he World Health Organisation (WHO) on Friday gave an emergency use listing to Sinopharm, China s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality, the UN health agency said in a press release. Courtesy file photo
GENEVA The World Health Organisation (WHO) on Friday gave an emergency use listing to Sinopharm, China s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality, the UN health agency said in a press release.
“The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” said Dr. Mariângela Simão, WHO assistant director-general for access to health products.